Accuitis Pharmaceuticals, Inc.
Accuitis is an early stage Bio-Tech start up focused on developing pharmaceuticals for under-served dermatological and ophthalmic diseases.
Accuitis has licensed technology from Emory University. Our lead compound (ACU-D1) is a first in class topical proteasome inhibitor which addresses inflammation and collagen-degradation. ACU-D1 is a potential therapy for Rosacea, Acne, Psoriasis and Skin Aging. We are initially seeking approval for Rosacea, a market opportunity > $1.5 Billion/year with very limited existing therapeutic options. Additional indications will follow thereafter.